ClinicalTrials.gg
RecruitingNCT07130994CASSINI-USUpdated Aug 10, 2026

Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

An interventional study of Mitral Valve Replacement in Mitral Regurgitation and Heart Disease, sponsored by InnovHeart. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by InnovHeart · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.

Planned enrollment
66th of 81
15 · median 60
Started
2026
with 9 others
No phase
64 of 118
21 open now
Primary completion
2027-09
later than 29 of 52 live
Registered
109th of 118
by date

Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 66th largest by planned enrollment of the 81 interventional ones that give a count, is one of 10 that started in 2026, is one of 64 with no phase, reaches primary completion later than 29 of the 52 other live ones, and was the 109th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Mitral Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US).

The purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.

Primary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.

Read the detailed description

The SATURN Bioprosthesis is designed to be implanted in the native mitral heart valve without open-heart surgery, extracorporeal circulation, cardiac arrest or removal of the failed native valve. The SATURN Bioprosthesis consists of the annular structure (Annular Segments) and the valve (SATURN Valve).

The valve supports a set of prosthetic leaflets that are the functional elements of the bioprosthesis. The valve is made of a self-expandable Nitinol frame supports three bovine pericardium leaflets. The valve is assembled with the annular structure through two connecting blocks mounted on the connecting arms of the stent.

The SATURN Delivery System and Accessories provides a transcatheter pathway to deliver the SATURN valve through the septum via the femoral vein. The SATURN Delivery System consists of an outer sheath, a guidewire delivery system, a valve delivery system and accessories.

The use of the SATURN TS System is carried out according to precise specifications and indications specified in the Instructions for Use (IFU) and is restricted to those physicians who have undergone dedicated training on use of the device.

Participants will be screened based on predefined inclusion and exclusion criteria. Eligible subjects will provide informed consent prior to any study-related procedures.

The clinical study designed to evaluate the safety, performance, and long-term clinical outcomes in adult patients with cardiac conditions. The study aims to collect comprehensive clinical data across patient population to support the understanding of procedural success, device-related outcomes, and patient recovery over time.

Participants will be followed from screening through five years post-procedure, with scheduled evaluations at the following timepoints: Screening, Baseline (pre-procedure), Intraprocedural, 24-48 hours post-procedure, 7 days or discharge, 1 month (±7 days), 3 months (±14 days), 6 months (±30 days), 1 year (±30 days), and annually through year five (±60 days).

Clinical assessments include physical examination, vital signs, and review of cardiac and antithrombotic medications. Functional status is evaluated using the Modified Rankin Scale, New York Heart Association (NYHA) classification, and the 6-Minute Walk Test. Quality of life is assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Risk stratification is performed at screening using EuroSCORE II and STS Risk Score.

Laboratory testing includes hematology, coagulation profiles, renal and liver function tests , and cardiac biomarkers such as NT-proBNP and plasma-free hemoglobin. Pregnancy testing is conducted at baseline for applicable participants.

Imaging and diagnostic testing includes transthoracic and transesophageal echocardiography (TTE/TEE), cardiac and vascular CT, gated cardiac CT at 6 months, 12-lead ECG, and intraprocedural assessments such as fluoroscopy, angiography, and right heart catheterization.

Safety endpoints include the incidence of adverse events (AEs), device deficiencies or malfunctions, and protocol deviations. The study is designed to generate robust clinical evidence supporting the intervention's safety, efficacy, and durability over time, and to inform future clinical practice and regulatory submissions.

03

Conditions studied

  • Mitral Regurgitation
  • Heart Disease

Keywords

  • Transcatheter
  • Mitral Valve
  • Replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Symptomatic, moderate to severe or severe, functional or mixed, mitral regurgitation (≥ Grade 3+).
  • functional Class ≥ II. If Class IV, patient must be ambulatory.
  • Ability to tolerate oral anticoagulation.
  • Ability to qualify for bailout surgery (which may include open heart surgery).
  • High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team.
  • Willing and able to complete study-related assessments and questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Purely degenerative (organic/primary) (i.e. intrinsic valve lesions) mitral regurgitation.
  • Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement.
  • \<1 yr. due to noncardiac conditions.
  • Endocarditis in the 3 months prior to procedure date.
  • Current admission with acute heart failure exacerbation.
  • Dependency on inotropic agents or mechanical circulatory support.
  • Untreated CAD.
  • Active systemic infection.
  • Modified Rankin Scale ≥4 disability.
  • Chronic renal failure defined as \< 30 mL/min/m2 or on renal replacement therapy.
  • Severe pulmonary arterial hypertension (PAH), defined as PASP > 70mmHg.
  • \< 90,000.
  • on home oxygen therapy deemed too high risk for intubation.
  • Refuses blood transfusions.
  • Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states).
  • Severe connective tissue disease under chronic or cortisone therapy.
  • Participating in other studies likely to confound the results or affect the study.
  • Unable or does not sign the study form.
  • Patients classified as "vulnerable patients"

Cardiovascular Exclusion Criteria

  • Myocardial infarction during prior 30 days.
  • Stroke or during prior 90 days.
  • Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed).
  • Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment.
  • Prior surgical mechanical valve AVR.
  • Prior TAVI. -Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure.
  • CRT, CRT-D, IPG or ICD implanted in previous 30 days.
  • Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure \<90mmHg, Inotropic dependent or IABP/mechanical circulatory support.

CABG or PCI within previous 30 days.

  • Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee.
  • Prior or planned heart transplantation (UNOS status 1).
  • Physical evidence of right-sided CHF:

    1. Patients with ascites.
    2. Patients with anasarca (generalized edema / hydropsy).
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy.

Procedural Exclusion Criteria

  • Known or to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy).
  • Documented hypersensitivity to nickel or titanium.

Cardiac Imaging Exclusion Criteria (evaluated by Core Labs)

  • Contraindications to TEE imaging
  • Left ventricular EF ≤ 30% by echocardiogram.
  • Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass.
  • Extensive mitral flail leaflets
  • Evidence of new or untreated intracardiac thrombus, mass, or vegetation.
  • Severe right ventricular dysfunction.
  • Severe tricuspid regurgitation.
  • Hemodynamically significant inter-atrial shunt (ASD).
  • Severe aortic regurgitation or aortic stenosis.
  • Anatomic ineligibility for SATURN Valve or SATURN TS procedure as determined by the Screening Committee.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    SATURN TMVR Cohort

    Saturn transseptal TMVR System implant

    Device: Mitral Valve Replacement

Interventions

  • DeviceMitral Valve Replacement

    Implant of SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation

06

What researchers measure

Primary outcomes

  1. Technical (Implant) Success Endpoint

    Presented as the n/N (%) of patients that meet the definition of Implant Success per protocol.

    Time frame: At completion of study procedure (Day 0)

  2. Freedom from Major Adverse Events Endpoint

    Freedom from (n/N, %) device-related or procedure-related major adverse events (MAE) which include: Cardiovascular death, Peri-procedural myocardial infarction, Disabling stroke, Major cardiac structural complication, Major vascular complication, and Mitral reintervention (operative or transcatheter) due to progressive or recurrent MR or device-related complications.

    Time frame: 30 days from index procedure

  3. Mitral Valve Effectiveness Endpoint (reduction in MR grade)

    Defined as the reduction of mitral regurgitation Grade to ≤1+ at 30 days.

    Time frame: 30 days post treatment

Secondary outcomes

  1. Mitral Valve Performance over time Endpoint

    Includes the following outcome measured at 30 days, 1 year and annually thereafter through 5 years post index procedure; -Reduction of MR grade compared to baseline and freedom from associated hemolysis

    Time frame: 5 years post index procedure

Other outcomes

  1. Additional Safety Measurements (Incidence of AEs)

    * All-cause mortality * All strokes * Acute kidney injury (AKI) * Mitral valve surgery or re-intervention * Re-hospitalizations for heart failure

    Time frame: Measured at 30 days, 1 year and annually thereafter through 5 years post index procedure

  2. Change in Quality of Life (KCCQ)

    The subject reported quality-of-life score (KCCQ) will be reported at each visit and compared to baseline. Scale 0-100, higher scores mean better outcomes.

    Time frame: Baseline, 30 days, 3 months, 6 months, 1 year and annually thereafter through 5 years post index procedure

  3. Change in NYHA Classification

    The physician reported NYHA assessment (I-IV) will be reported at each visit and compared to baseline. Scale I-IV, higher score means a worse outcome.

    Time frame: Baseline, 30 days, 3 months, 6 months, 1 year and annually thereafter through 5 years post index procedure

  4. Change in Six Minute Walk Test (6MWT)

    The distance walked (m) during the 6MWT will be reported at each visit and compared to baseline.

    Time frame: Baseline, 30 days, 3 months, 6 months, 1 year and annually thereafter through 5 years post index procedure

07

Study locations

2 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 13 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 19, 2025
StartActual
Aug 5, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2032
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07130994
Lead sponsor
InnovHeart
Collaborators
Avania
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Aug 5, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2032 (estimated)
Last update
Aug 10, 2026

Study contacts

Angelic Roach, MSc
Contact
a.roach@innovheart.com
+39 0125538873
David Wilson
Contact
d.wilson@innovheart.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion